These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 2268202

  • 41. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu, Klepikov PV, Lashutin SV.
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract] [Full Text] [Related]

  • 42. [Erythropoietin: from established therapeutic procedures in renal anemia to future areas of use].
    Marsen TA, Pollok M, Baldamus CA.
    Med Klin (Munich); 1992 Apr 15; 87(4):207-14. PubMed ID: 1579099
    [No Abstract] [Full Text] [Related]

  • 43. The long-term effects of recombinant human erythropoietin on the cardiovascular system.
    Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR.
    Clin Nephrol; 1992 Apr 15; 38 Suppl 1():S98-103. PubMed ID: 1295715
    [Abstract] [Full Text] [Related]

  • 44. [Erythropoietin: its biological properties and clinical use].
    Ermolenko VM, Nikolaev AIu.
    Ter Arkh; 1990 Apr 15; 62(11):141-5. PubMed ID: 2094979
    [No Abstract] [Full Text] [Related]

  • 45. Does erythropoietin cause epilepsy.
    Cengiz K, Işlek I.
    Nephron; 1996 Apr 15; 73(2):320-1. PubMed ID: 8773367
    [No Abstract] [Full Text] [Related]

  • 46. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
    Suzuki M.
    Contrib Nephrol; 1990 Apr 15; 82():65-71. PubMed ID: 2093529
    [No Abstract] [Full Text] [Related]

  • 47. [Improvement of the quality of life for hemodialysis patients using recombinant human erythropoietin].
    Schaefer RM.
    Krankenpfl J; 1988 Apr 15; 26(7-8):317-20. PubMed ID: 3419139
    [No Abstract] [Full Text] [Related]

  • 48. [Erythropoietin, aluminum and renal anemia].
    Schaefer M, Heidland A.
    Dtsch Med Wochenschr; 1990 Jun 01; 115(22):878-9. PubMed ID: 2347300
    [No Abstract] [Full Text] [Related]

  • 49. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M, Uday K, Henriquez M, Blum S, Dave M.
    Clin Nephrol; 1997 Jul 01; 48(1):63-4. PubMed ID: 9247787
    [No Abstract] [Full Text] [Related]

  • 50. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT.
    Contrib Nephrol; 1989 Jul 01; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract] [Full Text] [Related]

  • 51. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA, Bioequivalence Study of Erythropoietin Group.
    BMC Nephrol; 2005 May 23; 6():5. PubMed ID: 15910687
    [Abstract] [Full Text] [Related]

  • 52. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R, Rodríguez-Benítez P, Villaverde MT, Valderrábano F.
    Nefrologia; 2001 May 23; 21(6):606-7. PubMed ID: 11881433
    [No Abstract] [Full Text] [Related]

  • 53. Effects of erythropoietin in predialysis patients.
    Anderson S.
    Am J Kidney Dis; 1991 May 23; 17(5 Suppl 1):103-6. PubMed ID: 2024665
    [No Abstract] [Full Text] [Related]

  • 54. L-carnitine and erythropoietin requirements in hemodialysis patients.
    Kavadias D, Fourtounas C, Tsouchnikas J, Barboutis K.
    Am J Kidney Dis; 1996 Jul 23; 28(1):156. PubMed ID: 8712214
    [No Abstract] [Full Text] [Related]

  • 55. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
    Sánchez Casajús A, Barrau J, Gómez Alamillo C, Jaurrieta F.
    Sangre (Barc); 1990 Feb 23; 35(1):82-4. PubMed ID: 2333585
    [Abstract] [Full Text] [Related]

  • 56. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
    Brunner R, Pollok M, Heidel M, Müller R, Degenhardt S, Baldamus CA.
    Contrib Nephrol; 1989 Feb 23; 76():306-12; discussion 312-4. PubMed ID: 2582784
    [No Abstract] [Full Text] [Related]

  • 57. Erythropoietin: a therapeutic tool.
    Agarwal MB.
    J Assoc Physicians India; 1992 Jan 23; 40(1):9-10. PubMed ID: 1634473
    [No Abstract] [Full Text] [Related]

  • 58. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W.
    Behring Inst Mitt; 1988 Aug 23; (83):188-92. PubMed ID: 3071336
    [Abstract] [Full Text] [Related]

  • 59. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
    Fujita Y, Inoue S, Horiguchi S, Kuki A.
    Miner Electrolyte Metab; 1995 Aug 23; 21(1-3):50-4. PubMed ID: 7565462
    [Abstract] [Full Text] [Related]

  • 60. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul 23; 317(4):249-51. PubMed ID: 3600716
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.